Thromboprophylaxis in the cancer patient

Haemostasis

Volumn 28, Issue SUPPL. 3, 1998, Pages 61-65

  Kakkar, Ajay K ^a   Williamson, Robin C N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Deep vein thrombosis; Low molecular weight heparin; Thromboprophylaxis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BREAST CANCER; CATHETER; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; TREATMENT PLANNING; VASCULAR ACCESS;

EID: 0032456926     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022406     Document Type: Conference Paper

References (17)

1. Kakkar AK, Deruvo N, Chinswangwatanakul V, Tebbalt S, Williamson RCN: Extrinsic pathway activation with elevated tissue factor and Factor VIIa in cancer. Lancet 1995;346:1004-1005.
2. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 1995;108:312-334.
3. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731-2737.
4. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH: Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-1268.
5. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hyniuk W, De Pauw S: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407.
6. Clagett GP, Reisch JS: Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-240.
7. International Multicentre Trial: Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975;2:45-51.
8. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341:259-265.
9. Bergqvist D, Burmark US: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg 1995;82:496-501.
10. Levine M, Hirsh J, Gent M: Double blind randomized trial of very low-dose warfarin for the prevention of thromboembolism in Stage IV breast cancer. Lancet 1994;343:886-889.
11. Bern MM, Lokich JJ, Wallach SR: Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Intern Med 1990;112:423-428.
12. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A: Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low-molecular-weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
13. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC: Effect of warfarin on survival in small-cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981;245:831-835.
14. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E: Subcutaneous heparin treatment increases survival in small-cell lung cancer. 'Petites Cellules' Group. Cancer 1994;74:38-45.
15. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982.
16. Prandoni P, Lensing AWA, Buller HRE: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992;339:441-445.
17. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin [letter]. Lancet 1992;339:1476.